Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity

Journal of Pharmaceutical Sciences

Volumn 97, Issue 6, 2008, Pages 2324-2339

  Jansson, Rasmus ^a   Bredberg, Ulf ^b   Ashton, Michael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

ADME; Clinical pharmacokinetics; Computational ADME; Distribution; Log P; Pharmacokinetics; Physiochemical properties; Physiological model; Preclinical pharmacokinetics; Tissue partition

Indexed keywords

5 BUTYL 5 ETHYL BARBITURIC ACID; 5 ETHYL 5 ETHYL BARBITURIC ACID; 5 HEPTYL 5 ETHYL BARBITURIC ACID; 5 NONYL 5 ETHYL BARBITURIC ACID; 5 PENTYL 5 ETHYL BARBITURIC ACID; 5 PROPYL 5 ETHYL BARBITURIC ACID; BARBITURIC ACID DERIVATIVE; BIPERIDEN; CARVEDILOL; CEFAZOLIN; CEFTAZIDIME; CLOMIPRAMINE; CLOTIAZEPAM; COTININE; DIAZEPAM; DICLOXACILLIN; FENTANYL; FLEROXACIN; HEXOBARBITAL; METICILLIN; NORFLOXACIN; PEFLOXACIN; PENICILLIN V; PENTOBARBITAL; PHENOBARBITAL; RETINOIC ACID; SPARFLOXACIN; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; ADIPOSE TISSUE; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; HAPLORHINI; METABOLISM; MOUSE; MUSCLE; PHARMACOKINETICS; RABBIT; RAT; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; ANIMALS; HAPLORHINI; MICE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MUSCLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RABBITS; RATS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 47749125276     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21130     Document Type: Article

References (83)

1. Brightman FA, Leahy DE, Searle GE, Thomas S. 2006. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab Dispos 34:84-93.
2. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
3. Parrott N, Paquereau N, Coassolo P, Lave T. 2005. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 94:2327-2343.
4. Nestorov I. 2003. Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
5. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS Pharm Sci 6:E6.
6. Poulin P, Schoenlein K, Theil FP. 2001. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
7. Poulin P, Theil FP. 2000. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
8. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
9. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
10. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
11. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. 2007. The prediction of drug metabolism, tissue distribution and bioavailability of 50 structurally diverse compounds in rat using mechanism-based ADME prediction tools. Drug Metab Dispos 35:649-659.
12. Arundel P. 3rd IFAC Symposium: Modelling and control in biomedical systems, Warwick, UK, March 23-26th 1997.
13. Bjorkman S. 2002. Prediction of the volume of distribution of a drug: Which tissue-plasma partition coefficients are needed? J Pharm Pharmacol 54: 1237-1245.
14. Leo A. 1971. Partition coefficients and their uses. Chem Rev 71:525-616.
15. Bernareggi A, Rowland M. 1991. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19:21-50.
16. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
17. Gueorguieva I, Nestorov IA, Murby S, Gisbert S, Collins B, Dickens K, Duffy J, Hussain Z, Rowland M. 2004. Development of a whole body physiologically based model to characterise the pharmacoki-netics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios. J Pharmacokinet Pharmacodyn 31:269-298.
18. Evans AM, Shanahan K. 1995. The disposition of morphine and its metabolites in the in-situ rat isolated perfused liver. J Pharm Pharmacol 47: 333-339.
19. Sawada Y, Hanano M, Sugiyama Y, Iga T. 1985. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 13:477-492.
20. Schoeffner DJ, Warren DA, Muralidara S, Bruckner JV, Simmons JE. 1999. Organ weights and fat volume in rats as a function of strain and age. J Toxicol Environ Health A 56:449-462.
21. Ballard P, Leahy DE, Rowland M. 2003. Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acids. Pharm Res 20:864-872.
22. Tsuji A, Miyamoto E, Terasaki T, Yamana T. 1979. Physiological pharmacokinetics of beta-lactam antibiotics: Penicillin V distribution and elimination after intravenous administration in rats. J Pharm Pharmacol 31:116-119.
23. Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH, Yamana T. 1983. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. J Pharm Sci 72:1239-1252.
24. Granero L, Santiago M, Cano J, Machado A, Peris JE. 1995. Analysis of ceftriaxone and ceftazidime distribution in cerebrospinal fluid of and cerebral extracellular space in awake rats by in vivo microdialysis. Antimicrob Agents Chemother 39:2728-2731.
25. Igari Y, Sugiyama Y, Awazu S, Hanano M. 1982. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J Pharmacokinet Biopharm 10:53-75.
26. Kobayashi S, Takai K, Iga T, Hanano M. 1990. Effect of pregnancy on the disposition of valproate in rats. J Pharmacobiodyn 13:533-542.
27. Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, Shimizu M. 1983. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother 24:54-60.
28. Chenel M, Barbot A, Dupuis A, Mimoz O, Paquereau J, Bouquet S, Couet W. 2003. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats. Antimicrob Agents Chemother 47:1952-1957.
29. Hayakawa H, Takagi K, Takano YF, Kawamura Y, Tsuji A. 2002. Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. J Pharm Pharmacol 54:1229-1236.
30. Matsunaga Y, Miyazaki H, Oh-e Y, Nambu K, Furukawa H, Yoshida K, Hashimoto M. 1991. Disposition and metabolism of [14C]sparfloxacin in the rat. Arzneimittelforschung 41:747-759.
31. Nightingale CH. 1993. Overview of the pharmacokinetics of fleroxacin. Am J Med 94:38S-43S.
32. Montay G, Goueffon Y, Roquet F. 1984. Absorption, distribution, metabolic fate, and elimination of pefioxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 25:463-472.
33. Yokogawa K, Nakashima E, Ishizaki J, Maeda H, Nagano T, Ichimura F. 1990. Relationships in the structure-tissue distribution of basic drugs in the rabbit. Pharm Res 7:691-696.
34. Nakashima E, Yokogawa K, Ichimura F, Hashimoto T, Yamana T, Tsuji A. 1987. Effects of fasting on biperiden pharmacokinetics in the rat. J Pharm Sci 76:10-13.
35. Fujimaki M. 1992. Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 4:148-154.
36. Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H. 1993. Carvedilol stereopharmacoki-netics in rats: Affinities to blood constituents and tissues. Arch Pharm (Weinheim) 326:529-533.
37. Sukbuntherng J, Martin DK, Pak Y, Mayersohn M. 1996. Characterization of the properties of cocaine in blood: Blood clearance, blood to plasma ratio, and plasma protein binding. J Pharm Sci 85:567-571.
38. Nayak PK, Misra AL, Mule SJ. 1976. Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats. J Pharmacol Exp Ther 196:556-569.
39. Pan WJ, Hedaya MA. 1999. Cocaine and alcohol interactions in the rat: Effect on cocaine pharmacokinetics and pharmacodynamics. J Pharm Sci 88:459-467.
40. Gabrielsson J, Bondesson U. 1987. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. J Pharmacokinet Biopharm 15:583-599.
41. Zomorodi K, Houston JB. 1995. Effect of omeprazole on diazepam disposition in the rat: In vitro and in vivo studies. Pharm Res 12:1642-1646.
42. Hanada K, Akimoto S, Mitsui K, Mihara K, Ogata H. 1998. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: Role of plasma protein and tissue phosphatidylserine binding. Pharm Res 15:1250-1256.
43. Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S, Ichimura F. 1998. Influence of ammonium chloride on the tissue distribution of anticholinergic drugs in rats. J Pharm Pharmacol 50:761-766.
44. Ishizaki J, Yokogawa K, Nakashima E, Ichimura F. 1997. Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients. J Pharm Pharmacol 49:762-767.
45. Bjorkman S, Stanski DR, Verotta D, Harashima H. 1990. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology 72:865-873.
46. Meuldermans WE, Hurkmans RM, Heykants JJ. 1982. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 257:4-19.
47. Obach RS. 1997. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
48. DeVane CL, Simpkins JW, Stout SA. 1984. Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat. Psycho-pharmacology (Berl) 84:225-230.
49. Nagata O, Murata M, Kato H, Terasaki T, Sato H, Tsuji A. 1990. Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate. Drug Metab Dispos 18:902-910.
50. Benowitz N, Forsyth FP, Melmon KL, Rowland M. 1974. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther 16:87-98.
51. Plowchalk DR, Andersen ME, deBethizy JD. 1992. A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. Toxicol Appl Pharmacol 116:177-188.
52. La Rosa C, Mather LE, Morgan DJ. 1984. Pethidine binding in plasma: Effects of methodological variables. Br J Clin Pharmacol 17:411-415.
53. La Rosa C, Morgan DJ, Mather LE. 1984. Pethidine binding in whole blood: Methodology and clinical significance. Br J Clin Pharmacol 17: 405-409.
54. Kukongviriyapan V, Simajareuk S, Kukong-viriyapan U, Cha-on U, Airarat W. 2001. Alteration of drug kinetics in rats following exposure to tri-chloroethylene. Pharmacology 63:90-94.
55. Mansor SM, Ward SA, Edwards G. 1991. The effect of fever on quinine and quinidine disposition in the rat. J Pharm Pharmacol 43:705-708.
56. Fremstad D. 1977. Increased plasma binding and decreased blood cell binding of quinidine in blood from anuric rats. Acta Pharmacol Toxicol (Copenh) 41:148-160.
57. Fremstad D, Jacobsen S, Lunde KM. 1977. Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. Acta Pharmacol Toxicol (Copenh) 41:161-176.
58. Evans RL, Owens SM, Ruch S, Kennedy RH, Seifen E. 1990. The effect of age on digoxin pharmacokinetics in Fischer-344 rats. Toxicol Appl Pharmacol 102:61-67.
59. Cano NJ, Sabouraud AE, Benmoussa K, Roquet F, Navarro-Teulon I, Mani JC, Scherrmann JM. 1995. Monoclonal digoxin-specific antibodies induce dose- and affinity-dependent plasma digoxin redistribution in rats. Pharm Res 12:709-714.
60. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Knott S, Ruane RJ. 1991. Distribution in female rats of an anaesthetic intravenous dose of 14C-propofol. Xenobiotica 21:1325-1335.
61. Cockshott ID, Douglas EJ, Plummer GF, Simons PJ. 1992. The pharmacokinetics of propofol in laboratory animals. Xenobiotica 22:369-375.
62. Yoshikawa T, Sugiyama Y, Sawada Y, Iga T, Hanano M. 1984. Effect of pregnancy on tissue distribution of salicylate in rats. Drug Metab Dispos 12:500-505.
63. Varma DR, Yue TL. 1984. Influence of age, sex, pregnancy and protein-calorie malnutrition on the pharmacokinetics of salicylate in rats. Br J Pharmacol 82:241-248.
64. Ebling WF, Wada DR, Stanski DR. 1994. From piecewise to full physiologic pharmacokinetic modeling: Applied to thiopental disposition in the rat. J Pharmacokinet Biopharm 22:259-292.
65. Bjorkman S, Redke F. 2000. Clearance of fentanyl, alfentanil, methohexitone, thiopentone and keta-mine in relation to estimated hepatic blood flow in several animal species: Application to prediction of clearance in man. J Pharm Pharmacol 52:1065-1074.
66. Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M. 1982. Physiologically based pharmacokinetics of drug-drug interaction: A study of tolbutamide-sul- fonamide interaction in rats. J Pharmacokinet Biopharm 10:297-316.
67. Itoh T, Sawada Y, Lin TH, Iga T, Hanano M. 1988. Kinetic analysis of phenytoin disposition in rats with experimental renal and hepatic diseases. J Pharmacobiodyn 11:289-308.
68. Kang HJ, Wientjes MG, Au JL. 1997. Physiologically based pharmacokinetic models of 2′,3′-dideoxyinosine. Pharm Res 14:337-344.
69. Nakajima Y, Hattori K, Shinsei M, Matsunaga N, Iizasa H, Sasabe H, Akiyama H, Miyanmoto G, Nakashima E. 2000. Physiologically-based pharmacokinetic analysis of grepafloxacin. Biol Pharm Bull 23:1077-1083.
70. Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y. 2002. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. Drug Metab Dispos 30:1393-1399.
71. Bjorkman S, Stanski DR, Harashima H, Dowrie R, Harapat SR, Wada DR, Ebling WF. 1993. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinet Biopharm 21:255-279.
72. Mandema JW, Wada DR. 1995. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J Pharmacol Exp Ther 275:1185-1194.
73. Curry SH. 1972. Relation between binding to plasma protein, apparent volume of distribution, and rate constants of disposition and elimination for chlorpromazine in three species. J Pharm Pharmacol 24:818-819.
74. Cheng YF, Paalzow LK. 1992. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13:69-76.
75. Kim HK, Hong JH, Park MS, Kang JS, Lee MH. 2001. Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. Biomed Chromatogr 15:539-545.
76. Bjorkman S, Fyge A, Qi Z. 1996. Determination of the steady state tissue distribution of midazolam in the rat. J Pharm Sci 85:887-889.
77. Vaille A, Balansard G, Jadot G. 1993. Effects of a subacute treatment in rats by a fresh cola extract on EEG and pharmacokinetics. Pharmacol Biochem Behav 45:791-796.
78. Latini R, Bonati M, Marzi E, Tacconi MT, Sadurska B, Bizzi A. 1980. Caffeine disposition and effects in young and one-year old rats. J Pharm Pharmacol 32:596-599.
79. Gabrielsson JL, Paalzow LK. 1983. A physiological pharmacokinetic model for morphine disposition in the pregnant rat. J Pharmacokinet Biopharm 11: 147-163.
80. Bhargava HN, Villar VM, Rahmani NH, Larsen AK. 1992. Distribution of morphine in brain regions, spinal cord and serum following intravenous injection to morphine tolerant rats. Brain Res 595:228-235.
81. Meyer HG, Lukey BJ, Gepp RT, Corpuz RP, Lieske CN. 1988. A radioimmunoassay for pyridostigmine. J Pharmacol Exp Ther 247:432-438.
82. Yamamoto K, Sawada Y, Iga T. 1995. Comparative pharmacokinetics of four cholinesterase inhibitors in rats. Biol Pharm Bull 18:1292-1295.
83. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. 1991. Pharmaco-kinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 257:472-478.